Loading...
XHKG2500
Market cap316mUSD
Nov 22, Last price  
5.62HKD
Name

Venus Medtech Hangzhou Inc

Chart & Performance

D1W1MN
XHKG:2500 chart
P/E
—
P/S
4.71
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.20%
Rev. gr., 5y
33.62%
Revenues
491m
+20.89%
18,164,000115,348,000233,272,000276,047,000415,862,000406,461,000491,373,000
Net income
-704m
L-37.28%
-156,532,000-300,421,000-380,765,000-182,868,000-371,394,000-1,122,042,000-703,754,000
CFO
-610m
L-16.37%
-82,266,000-151,467,000-303,291,000-237,005,000-456,917,000-729,459,000-610,019,000
Earnings
Mar 26, 2025

Profile

Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
URL
https://www.venusmedtech.com/
IPO date
Dec 10, 2019
Employees
1,006
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
491,373
20.89%
406,461
-2.26%
415,862
50.65%
Cost of revenue
1,081,346
1,072,474
694,506
Unusual Expense (Income)
NOPBT
(589,973)
(666,013)
(278,644)
NOPBT Margin
Operating Taxes
(6,284)
(34,302)
(6,161)
Tax Rate
NOPAT
(583,689)
(631,711)
(272,483)
Net income
(703,754)
-37.28%
(1,122,042)
202.12%
(371,394)
103.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,118,784
BB yield
-8.62%
Debt
Debt current
494,700
246,060
22,627
Long-term debt
451,765
757,244
114,023
Deferred revenue
600
Other long-term liabilities
357,714
487,826
167,480
Net debt
(345,167)
(1,353,207)
(3,392,408)
Cash flow
Cash from operating activities
(610,019)
(729,459)
(456,917)
CAPEX
(260,636)
(178,774)
(145,164)
Cash from investing activities
(346,859)
(1,072,266)
(653,038)
Cash from financing activities
(173,986)
635,137
1,391,401
FCF
(979,759)
(887,180)
(465,083)
Balance
Cash
781,636
1,879,431
2,955,212
Long term investments
509,996
477,080
573,846
Excess cash
1,267,063
2,336,188
3,508,265
Stockholders' equity
(2,120,382)
(1,408,417)
(407,884)
Invested Capital
6,223,628
6,422,791
5,277,503
ROIC
ROCE
EV
Common stock shares outstanding
437,897
437,897
438,577
Price
14.26
-51.82%
29.60
-62.65%
Market cap
6,244,418
-51.90%
12,981,880
-59.97%
EV
4,914,658
9,675,686
EBITDA
(465,186)
(553,661)
(227,023)
EV/EBITDA
Interest
62,716
44,623
1,905
Interest/NOPBT